425 related articles for article (PubMed ID: 28649132)
1. Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
Zhang QS; Heng Y; Mou Z; Huang JY; Yuan YH; Chen NH
Acta Pharmacol Sin; 2017 Oct; 38(10):1317-1328. PubMed ID: 28649132
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
3. Dose-related biphasic effect of the Parkinson's disease neurotoxin MPTP, on the spread, accumulation, and toxicity of α-synuclein.
Merghani MM; Ardah MT; Al Shamsi M; Kitada T; Haque ME
Neurotoxicology; 2021 May; 84():41-52. PubMed ID: 33549656
[TBL] [Abstract][Full Text] [Related]
4. Continuous MPTP intoxication in the Göttingen minipig results in chronic parkinsonian deficits.
Nielsen MS; Glud AN; Møller A; Mogensen P; Bender D; Sørensen JC; Doudet D; Bjarkam CR
Acta Neurobiol Exp (Wars); 2016; 76(3):199-211. PubMed ID: 27685773
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effects of Astilbin on MPTP-induced Parkinson's disease mice: Glial reaction, α-synuclein expression and oxidative stress.
Zhu YL; Sun MF; Jia XB; Cheng K; Xu YD; Zhou ZL; Zhang PH; Qiao CM; Cui C; Chen X; Yang XS; Shen YQ
Int Immunopharmacol; 2019 Jan; 66():19-27. PubMed ID: 30419450
[TBL] [Abstract][Full Text] [Related]
6. Mulberry fruit ameliorates Parkinson's-disease-related pathology by reducing α-synuclein and ubiquitin levels in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model.
Gu PS; Moon M; Choi JG; Oh MS
J Nutr Biochem; 2017 Jan; 39():15-21. PubMed ID: 27741433
[TBL] [Abstract][Full Text] [Related]
7. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain-derived neurotrophic factor.
Komnig D; Dagli TC; Habib P; Zeyen T; Schulz JB; Falkenburger BH
J Neurochem; 2018 Dec; 147(5):678-691. PubMed ID: 30152864
[TBL] [Abstract][Full Text] [Related]
9. Whether the Subacute MPTP-Treated Mouse is as Suitable as a Classic Model of Parkinsonism.
Qi Y; Zhang Z; Li Y; Zhao G; Huang J; Zhang Y; Xue J; Tang X
Neuromolecular Med; 2023 Sep; 25(3):360-374. PubMed ID: 36913134
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
11. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
Sconce MD; Churchill MJ; Greene RE; Meshul CK
Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
[TBL] [Abstract][Full Text] [Related]
12. Papaverine inhibits α-synuclein aggregation by modulating neuroinflammation and matrix metalloproteinase-3 expression in the subacute MPTP/P mouse model of Parkinson's disease.
Leem YH; Park JS; Park JE; Kim DY; Kang JL; Kim HS
Biomed Pharmacother; 2020 Oct; 130():110576. PubMed ID: 32768884
[TBL] [Abstract][Full Text] [Related]
13. Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
Heng Y; Zhang QS; Mu Z; Hu JF; Yuan YH; Chen NH
Toxicol Lett; 2016 Jan; 243():7-21. PubMed ID: 26723869
[TBL] [Abstract][Full Text] [Related]
14. Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets.
Ando K; Maeda J; Inaji M; Okauchi T; Obayashi S; Higuchi M; Suhara T; Tanioka Y
Psychopharmacology (Berl); 2008 Jan; 195(4):509-16. PubMed ID: 17879087
[TBL] [Abstract][Full Text] [Related]
15. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.
Gibrat C; Saint-Pierre M; Bousquet M; Lévesque D; Rouillard C; Cicchetti F
J Neurochem; 2009 Jun; 109(5):1469-82. PubMed ID: 19457163
[TBL] [Abstract][Full Text] [Related]
16. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
[TBL] [Abstract][Full Text] [Related]
17. 7,8-dihydroxyflavone Ameliorates Motor Deficits Via Suppressing α-synuclein Expression and Oxidative Stress in the MPTP-induced Mouse Model of Parkinson's Disease.
Li XH; Dai CF; Chen L; Zhou WT; Han HL; Dong ZF
CNS Neurosci Ther; 2016 Jul; 22(7):617-24. PubMed ID: 27079181
[TBL] [Abstract][Full Text] [Related]
18. LLDT-67 attenuates MPTP-induced neurotoxicity in mice by up-regulating NGF expression.
Wu DD; Huang L; Zhang L; Wu LY; Li YC; Feng L
Acta Pharmacol Sin; 2012 Sep; 33(9):1187-94. PubMed ID: 22941283
[TBL] [Abstract][Full Text] [Related]
19. Eupatilin prevents behavioral deficits and dopaminergic neuron degeneration in a Parkinson's disease mouse model.
Zhang Y; Qin L; Xie J; Li J; Wang C
Life Sci; 2020 Jul; 253():117745. PubMed ID: 32376269
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
Guo Z; Xu S; Du N; Liu J; Huang Y; Han M
Neurosci Lett; 2016 Mar; 616():152-9. PubMed ID: 26827716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
